1-8 of 8
Rosalba Martignetti
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma

Free
Anita Kumar, Jacob Soumerai, Reem Karmali, Jeremy Abramson, Jeffrey Barnes, Bernadette Beatty, Jason Brecher, Philip Caron, Kenneth Carson, Maria Chabowska, Madelyn Coogan, Jayne Coyle, Kevin David, Meemanage De Zoysa, Ahmet Dogan, Zachary Epstein-Peterson, Paola Ghione, Cameron Gordan, Leo Gordon, Julie Haydu, Ephraim Hochberg, Patrick Connor Johnson, Ashlee Joseph, Akshata Kakolu, Alyssa Labarre, Carissa Laudati, Jennifer Lue, Shuo Ma, Rosalba Martignetti, Colette Owens, Olivia Maas, Joanna Mi, Rachel Nazzaro, James O'Grady, Jessica Pendleton, Gilles Salles, Venkatraman Seshan, Natalie Slupe, Pallawi Torka, Andrew Zelenetz
Journal: Blood
Blood (2025) 146 (Supplement 1): 888.
https://doi.org/10.1182/blood-2025-888
Published: 2025
Journal Articles

Post-treatment outcomes of TP53-mutant Mantle Cell Lymphoma patients treated with frontline zanubrutinib, obinutuzumab, and venetoclax (BOVen): Durable responses in patients who achieve complete remissions with undetectable MRD

Free
Sean Healton, Jacob Soumerai, Jeffrey Barnes, Jason Brecher, Philip Caron, Shalini Chhabra, Maria Chabowska, Ahmet Dogan, Lorenzo Falchi, Clare Grieve, Erika Haydu, Patrick Connor Johnson, Ashlee Joseph, Alyssa Labarre, Jennifer Lue, Rosalba Martignetti, Joanna Mi, Alison Moskowitz, Colette Owens, Sean Plummer, Madeline Puccio, Venkatraman Seshan, Elizabeth Simkins, Natalie Slupe, Honglei Zhang, Gilles Salles, Andrew Zelenetz, Anita Kumar
Journal: Blood
Blood (2025) 146 (Supplement 1): 3569.
https://doi.org/10.1182/blood-2025-3569
Published: 2025
Journal Articles

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a  TP53 mutation

Available to Purchase
Clinical Trials & Observations
Anita Kumar, Jacob Soumerai, Jeremy S. Abramson, Jeffrey A. Barnes, Philip Caron, Shalini Chhabra, Maria Chabowska, Ahmet Dogan, Lorenzo Falchi, Clare Grieve, J. Erika Haydu, Patrick Connor Johnson, Ashlee Joseph, Hailey E. Kelly, Alyssa Labarre, Jennifer Kimberly Lue, Rosalba Martignetti, Joanna Mi, Alison Moskowitz, Colette Owens, Sean Plummer, Madeline Puccio, Gilles Salles, Venkatraman Seshan, Elizabeth Simkins, Natalie Slupe, Honglei Zhang, Andrew D. Zelenetz
Journal: Blood
Blood (2025) 145 (5): 497–507.
https://doi.org/10.1182/blood.2024025563
Published: 2025
Includes: Supplemental data
Journal Articles

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Free
Jacob D. Soumerai, Ahmet Dogan, Venkatraman Seshan, Kelsey Leigh Flaherty, Natalie Slupe, Jason Carter, Ephraim Hochberg, Jeffrey A. Barnes, Jeremy S. Abramson, Audrey Hamilton, Ariela Noy, Colette Owens, Maria Lia Palomba, Anita Kumar, Lindsey Roeker, Meghan C. Thompson, Ronald W. Takvorian, Zachary D. Epstein-Peterson, Mark Blaine Geyer, Gilles Salles, Robert Stuver, Philip Caron, Prioty Islam, Tamanna Haque, Paola Ghione, Raphael E. Steiner, Pallawi Torka, Kevin A. David, Jennifer Kimberly Lue, Paul A. Hamlin, Alison Moskowitz, Lorenzo Falchi, Julie Haydu, Patrick Connor Johnson, Joanna Mi, Jessica Pendleton, Alyssa Labarre, Rosalba Martignetti, Sean F. Plummer, Maria Chabowska, Walter Ramos Amador, Neena Mahajan, Morgan Choma, Clare Grieve, Rayna N. Garcia, Hailey E. Kelly, Ella Mallinger, James O'Grady, Bernadette Beatty, Michelle Adams, Athina Apazidis, Aileen Cleary Cohen, Mina Shahkarami, Allison P. Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz
Journal: Blood
Blood (2024) 144 (Supplement 1): 1867.
https://doi.org/10.1182/blood-2024-205697
Published: 2024
Journal Articles

A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, TP53 -Mutant Mantle Cell Lymphoma

Free
Anita Kumar, Jacob Soumerai, Jeremy S. Abramson, Jeffrey A. Barnes, Philip Caron, Maria Chabowska, Mary Devlin, Ahmet Dogan, Lorenzo Falchi, Rayna N. Garcia, Clare Grieve, Emma Haskell, Julie E. Haydu, Patrick Connor Johnson, Ashlee Joseph, Hailey E. Kelly, Alyssa Labarre, Emerald D Littlejohn, Jennifer Kimberly Lue, Joanna Mi, Rosalba Martignetti, Grace McCambridge, Alison Moskowitz, Colette Owens, Sean F. Plummer, Madeline G. Puccio, Gilles Salles, Venkatraman Seshan, Natalie Slupe, Andrew D. Zelenetz
Journal: Blood
Blood (2023) 142 (Supplement 1): 738.
https://doi.org/10.1182/blood-2023-180069
Published: 2023
Journal Articles

A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach

Free
Lindsey E. Roeker, Lori A. Leslie, Jake D. Soumerai, Victoria Falco, Gail Panton, Andrew D. Zelenetz, Lorenzo Falchi, Jae H Park, Camila Pena-Velasquez, Sonia Lebowitz, Kristen Battiato, Carissa Laudati, Meghan C. Thompson, David J. Straus, Yehudit Fox, Elizabeth McCarthy, Sabrina Kdiry, Rosalba Martignetti, Hari P. Miskin, Peter Sportelli, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 395.
https://doi.org/10.1182/blood-2021-146999
Published: 2021
Journal Articles

Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)

Free
Anita Kumar, Jacob D. Soumerai, Jeremy S. Abramson, Connie Lee Batlevi, Puja Chadha, Ahmet Dogan, Lorenzo Falchi, Kelsey Flaherty, Chaya Friedman, Clare Grieve, Caleb Ho, P. Connor Johnson, Ashlee Joseph, Niloufer Khan, Joanna Mi, Rosalba Martignetti, Matthew J. Matasar, Colette Owens, Jade Ruiters, Sidney Sechio, Venkatraman Seshan, Elizabeth Simkins, Omar Abdel-Wahab, Andrew D. Zelenetz
Journal: Blood
Blood (2021) 138 (Supplement 1): 3540.
https://doi.org/10.1182/blood-2021-151831
Published: 2021
Journal Articles

Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence

Free
Jacob D. Soumerai, Anthony R. Mato, Ahmet Dogan, Venkatraman Seshan, Erel Joffe, Kelsey Flaherty, Jason Carter, Ephraim P Hochberg, Jeffrey A Barnes, Audrey Hamilton, Jeremy S. Abramson, Connie Lee Batlevi, Matthew J. Matasar, Ariela Noy, Colette Owens, M. Lia Palomba, Anita Kumar, Tak Takvorian, Ai Ni, Morgan Choma, Chaya Friedman, Puja Chadha, Elizabeth Simkins, Jade Ruiters, Sidney Sechio, Daneal Portman, Natascha Nolet, Neena Mahajan, Rosalba Martignetti, Joanna Mi, Krista J Scorsune, Julia M Lynch, Brianne McGree, Stephanie Y Hughes, Clare Grieve, Lindsey E. Roeker, Meghan C. Thompson, P. Connor Johnson, Mikhail Roshal, Jane Huang, Juliana M.L. Biondo, Jenny Qun Wu, Allison P. Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz
Journal: Blood
Blood (2021) 138 (Supplement 1): 3753.
https://doi.org/10.1182/blood-2021-150961
Published: 2021